Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
11.04 EUR | 0.00% |
|
0.00% | -3.24% |
15/07 | INDEX-MONITOR: Medios replaces Synlab in the SDax | DP |
15/07 | SYNLAB AG(XTRA:SYAB) dropped from Germany SDAX (Total Return) Index | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company appears to be poorly valued given its net asset value.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company does not generate enough profits, which is an alarming weak point.
- The company is in debt and has limited leeway for investment
- With an expected P/E ratio at 29.89 and 36.87 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.24% | 2.65B | - | ||
-16.93% | 8.48B | B+ | ||
+81.25% | 4.81B | C+ | ||
+16.31% | 2.99B | B- | ||
-3.96% | 2.02B | C- | ||
-52.37% | 1.87B | B- | ||
-13.25% | 1.58B | A- | ||
+21.59% | 1.25B | B+ | ||
-47.00% | 1.06B | C+ | ||
-5.63% | 1B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- SYAB Stock
- SYAB Stock
- Ratings SYNLAB AG